tetano
Editor, Senior Moderator
Clin Exp Rheumatol. 2020 Mar 22. [Epub ahead of print]
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Sarzi-Puttini P[SUP]1[/SUP], Giorgi V[SUP]2[/SUP], Sirotti S[SUP]2[/SUP], Marotto D[SUP]3[/SUP], Ardizzone S[SUP]4[/SUP], Rizzardini G[SUP]5[/SUP], Antinori S[SUP]6[/SUP], Galli M[SUP]6[/SUP].
Author information
Abstract
A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.
PMID:32202240
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Sarzi-Puttini P[SUP]1[/SUP], Giorgi V[SUP]2[/SUP], Sirotti S[SUP]2[/SUP], Marotto D[SUP]3[/SUP], Ardizzone S[SUP]4[/SUP], Rizzardini G[SUP]5[/SUP], Antinori S[SUP]6[/SUP], Galli M[SUP]6[/SUP].
Author information
Abstract
A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.
PMID:32202240